The FIBOBS study is a multi-centered, observational, prospective study carried out within specialized chronic pain structures (CPS) in France. It will estimate the prevalence of sleep disorders, divided into three categories (poor quality of sleep in general, sleep apnea syndrome, restless legs syndrome), using self-questionnaires in patients with Fibromyalgia Syndrome (FMS) consulting within a CPS. The interaction between these sleep disorders and other symptoms of FMS will also be analyzed using self-administered questionnaires. Based on the hypothesis that sleep disorders associated with FMS are only imperfectly assessed and/or treated in CPS, the FIBOBS study will also interview pain physician in order to know both the diagnostic tools used and the recommended management when sleep disorders are suspected in the context of FMS. In addition, this study will provide a better understanding of the symptoms of FMS, their impact and how patients feel.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
601
Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
CHU Amiens Picardie - CETD
Amiens, France
CH Ardèche Méridionale
Aubenas, France
CH Henri Mondor
Aurillac, France
CHU Jean Minjoz - CETD
Besançon, France
CH Béziers
Béziers, France
HIA Clermont Tonnerre
Brest, France
Assessing the prevalence of sleep disorders in general in patients with FMS
The prevalence of sleep disorders will be estimated from the results of the Pittsburgh Sleep Quality Index Questionnaire (PSQI) which is a generic, validated 19-item self-administered questionnaire for measuring sleep problems.
Time frame: Only once, by the patient within 14 days of inclusion.
Assessing the prevalence of sleep disorders for the specific risk of sleep apnea syndrome in patients with FMS
The prevalence of sleep disorders for the specific risk of sleep apnea syndrome will be estimated from the results of the STOP-BANG questionnaire. This questionnaire guide the diagnosis of sleep apnea syndrome and is composed of 8 items.
Time frame: Only once, by the patient within 14 days of inclusion.
Assessing the prevalence of sleep disorders for the specific risk of restless legs syndrome in patients with FMS
The prevalence of sleep disorders will be estimated from the results of the simple question which is a rapid screening tool that provides a diagnosis of probable restless legs syndrome (RLS). Patients who answer positively to this question will complete the International Restless Legs Syndrome (IRLS) questionnaire which assesses the severity of restless legs syndrome on four levels: mild, moderate, severe and very severe.
Time frame: Only once, by the patient within 14 days of inclusion.
Assessing the pain severity of FMS
The pain severity of the FMS will be assessed using the WPI (widespread pain index) questionnaire, which represents the generalized pain index.
Time frame: Only once, by the patient within 14 days of inclusion.
Assessing the symptom severity of FMS
The symptom severity of the FMS will be assessed using the SSS (symptom severity scale) questionnaire, which corresponds to the symptom severity scale.
Time frame: Only once, by the patient within 14 days of inclusion.
Assessing the impact of the FMS on the patient's daily life
The impact of the FMS on the patient's daily life will be assessed by the QIF (French version of the Fibromyalgia Impact Questionnaire (FIQ)). This validated and commonly used questionnaire makes it possible to evaluate the functional incapacity and the repercussions of the FMS on daily life by evaluating the major symptoms: pain, fatigue, sleep disorders but also morning stiffness, anxiety and depression.
Time frame: Only once, by the patient within 14 days of inclusion.
Assessing the feeling of pain and the impact of pain on the patient's daily behavior
The painful feeling and the impact of pain on the patient's daily behavior will be assessed by the Concise Pain Questionnaire (QCD), the French version of the Brief Pain Inventory (BPI). This validated questionnaire makes it possible to assess the impact of pain on seven general aspects of the patient's life.
Time frame: Only once, by the patient within 14 days of inclusion.
Assess the patient's state of anxiety and depression
The patient's state of anxiety and depression will be assessed using the validated HADS - Hospital Anxiety and Depression Scale questionnaire.
Time frame: Only once, by the patient within 14 days of inclusion.
Describe the assessment tools used by the pain physician to evaluate the main symptoms of FMS (pain, asthenia, sleep and cognitive disorders)
The assessment tools used by the pain physician to evaluate patients' pain, asthenia, sleep disorders and memory problems will be recorded in the "physician questionnaire".
Time frame: Only once, by the pain physician at the inclusion.
Describe the therapeutic measures (drug and non-drug) in place for the management of FMS
Therapeutics proposed for the management of symptoms associated with FMS will be identified (names of drug and non-drug treatments, care practices).
Time frame: Once by the physician at the inclusion, and once by the patient within 14 days of inclusion.
Assess the percentage of patients for whom sleep disorders have been previously diagnosed and treated.
The "patient questionnaire" will identify patients already diagnosed and treated for a sleep disorder. This will allow comparison with the prevalence calculated from the three screening questionnaires.
Time frame: Throught study completion, an average of 4 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU Hôpital Côte de Nacre - CETD
Caen, France
CH Métropole Savoie
Chambéry, France
CH de Chartres
Chartres, France
CHU Gabriel Montpied
Clermont-Ferrand, France
...and 36 more locations